Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will

Novocure Reports Third Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Third Quarter 2022 Financial Results


Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting


Novocure (NASDAQ: NVCR) today announced 11 poster presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting from

Premier, Inc. Declares Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common

Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology


Novocure (NASDAQ: NVCR) today announced a review article of anti-cancer mechanisms of action of Tumor Treating Fields (TTFields) has been published in the Journal of Molecular Cell Biology (JMCB).

Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy


Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an

Premier, Inc. Issues 2022 Sustainability Report: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Issues 2022 Sustainability Report


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today released its 2022 Sustainability Report detailing its companywide initiatives focused on

Premier, Inc.'s Subsidiary Contigo Health, LLC, Completes Asset Transaction for National Provider Contracts and Licenses to Cost Containment Technology: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc.'s Subsidiary Contigo Health, LLC, Completes Asset Transaction for National Provider Contracts and Licenses to Cost Containment Technology


Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today closed its transaction to acquire key assets from

Acadia Healthcare Announces Date for Third Quarter 2022 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for Third Quarter 2022 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2022 results on Monday, October 31, 2022, after the close of the market. Acadia will conduct a

Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven

Premier, Inc. to Report Fiscal 2023 First-Quarter Results and Host Conference Call on November 1, 2022: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2023 First-Quarter Results and Host Conference Call on November 1, 2022


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 first quarter on Tuesday, November 1, 2022, at approximately 6:30 a.m. ET. The company will

Novocure to Report Third Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Report Third Quarter 2022 Financial Results


Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open. Novocure management

Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business


Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve

Thomas Jefferson University and Acadia Healthcare Establish Primary Affiliation Agreement: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Thomas Jefferson University and Acadia Healthcare Establish Primary Affiliation Agreement


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) and Thomas Jefferson University today announced that Acadia’s Belmont Behavioral Health Hospital has entered into a formal affiliation agreement with

Select Acadia Healthcare Hospitals to Participate in Clinical Trial for Acute Suicidal Ideation and Behavior in Major Depression Drug: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Select Acadia Healthcare Hospitals to Participate in Clinical Trial for Acute Suicidal Ideation and Behavior in Major Depression Drug


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that select facilities from its network of acute care behavioral health hospitals will participate in a registration directed trial to

Xencor Appoints Nancy Valente, M.D., to Board of Directors: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Appoints Nancy Valente, M.D., to Board of Directors


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the

Premier, Inc.’s Subsidiary Contigo Health, LLC, to Acquire Contracts With 900,000 Providers and Licenses to Cost Containment Technology: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc.’s Subsidiary Contigo Health, LLC, to Acquire Contracts With 900,000 Providers and Licenses to Cost Containment Technology


Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today announced an agreement to acquire key assets from

Novocure to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Participate in Upcoming Investor Conferences


Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will

Premier, Inc. Reports Fiscal-Year 2022 Fourth-Quarter and Full-Year Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2022 Fourth-Quarter and Full-Year Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2022 fourth quarter and full year ended June 30, 2022

Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility


On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure’s leadership team to tour the company’s U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure’s

Premier, Inc. Declares an Increase to Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares an Increase to Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors approved a 5% increase to the company’s quarterly cash dividend

Xencor Reports Second Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Second Quarter 2022 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial

Novocure Reports Second Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Second Quarter 2022 Financial Results


Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms